BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 28, 2026
See today's BioWorld
Home
» US FDA advises on ctDNA as a biomarker for certain early stage cancers
To read the full story,
subscribe
or
sign in
.
US FDA advises on ctDNA as a biomarker for certain early stage cancers
May 2, 2022
By
Mari Serebrov
The latest in a spate of draft and final guidances released recently by the U.S. FDA could help sponsors developing drugs to treat early stage solid tumor malignancies.
BioWorld
Regulatory
Cancer
Gastrointestinal
U.S.
FDA